Related Experiment Video
Updated: Feb 14, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
c-Raf in KRas Mutant Cancers: A Moving Target
1University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Abstract:
Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRasG12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.
Insights
Targeting c-Raf halts KRas G12V cancer growth. Ablating c-Raf regressed advanced KRas G12V/Trp53 tumors with no systemic toxicity, validating it as a key therapeutic target for KRas cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- KRas-driven cancers represent a significant unmet clinical need, lacking effective targeted therapies.
- The Ras-MAPK signaling pathway is frequently dysregulated in various cancers, including KRas-driven malignancies.
Purpose of the Study:
- To investigate the therapeutic potential of targeting c-Raf in KRas-driven cancers.
- To validate c-Raf as a druggable target for KRas-mutant and Trp53-mutant tumors.
Main Methods:
- Utilized genetic ablation of c-Raf in preclinical models of KRas-driven cancer.
- Assessed tumor regression and systemic toxicity following c-Raf inhibition.
- Analyzed the impact of c-Raf ablation on MAPK signaling pathways.
Main Results:
- c-Raf ablation led to the regression of advanced KRasG12V/Trp53-mutant tumors.
- The observed tumor regression occurred without significant systemic toxicity.
- MAPK signaling remained unaffected despite c-Raf ablation, suggesting a context-dependent role.
Conclusions:
- c-Raf is a validated and effective therapeutic target for KRas-mutant cancers, particularly those co-occurring with Trp53 mutations.
- Targeting c-Raf offers a promising strategy for treating KRas-driven tumors with minimal side effects.
- Further investigation into the precise mechanisms of c-Raf in KRas cancer is warranted.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Magnetic Field due to Moving Charges
Consider a point charge moving with a constant velocity. Like the electric field, the magnetic field at any point is directly proportional to the magnitude of the charge and inversely proportional to the square of the distance between the source point and the field point. However, unlike the electric field, the magnetic field is always perpendicular to the plane containing the line...
Conservation of Mass in Moving, Nondeforming Control Volume
In the context of a detention basin, the conservation of mass states that the total mass of water entering the basin must equal the mass leaving the basin plus any accumulation of...
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

